UCB
About
You see, UCB wants to be a world leader when it comes to treating ailments related to the immune and central nervous systems (CNS).
- Brussels,Brussels Hoofdstedelijk Gewest,Belgium
- 10001 - max
- http://www.ucb.com
Details
- Last Funding Type
- Post-IPO Equity
- Last Funding Money Raised
- €94.50M
- Industries
- Biotechnology,Health Care,Pharmaceutical
- Founded date
- Jan 1, 1928
- Number Of Employee
- 10001 - max
- Operating Status
- Active
- Stock Symbol
- ebr:UCB
- Legal Name
- UCB S.A.
UCB Pharma operates as a biopharmaceutical company with a focus on neurology and immunology diseases. The company leverages scientific advances and skills in areas such as genetics, biomarkers, and human biology.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| May 24, 2022 | Post-IPO Equity | €94.50M | 1 |
Financière de Tubize SA
|
— | Detail |
| May 13, 2015 | Post-IPO Equity | $787.62K | — | — | — | Detail |
| Dec 22, 2009 | Post-IPO Equity | $100M | 1 |
Paul Capital
|
— | Detail |
| Jan 7, 2000 | IPO | — | — | — | — | Detail |
Investments
|
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
|---|---|---|---|---|
|
Oct 4, 2022
Bingli
|
Series A | €5.40M | Apps | — |
|
Jan 13, 2021
Nile AI
|
Corporate Round | €25M | Artificial Intelligence | Yes |
|
Feb 5, 2019
Aetion
|
Series B | $27M | Analytics | — |
|
Sep 25, 2018
Ceribell
|
Series B | $35M | Biotechnology | — |
|
Jun 13, 2018
StrideBio
|
Series A | $15.70M | Biotechnology | — |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Financière de Tubize SA
|
Yes | Post-IPO Equity |
|
Paul Capital
|
Yes | Post-IPO Equity |
Employee Profiles
Exits
UCB has had 3 exits. UCB most notable exits include Clementia Pharmaceuticals , Dermira
| Date | Company Name | Exit Type | Industry | |
|---|---|---|---|---|
| Aug 22, 2017 | Clementia Pharmaceuticals | M&A | Biopharma | Detail |
| Oct 3, 2014 | Dermira | M&A | Biopharma | Detail |
| Jan 11, 2011 | Synosia Therapeutics | M&A | Biotechnology | Detail |
Acquisition
UCB has acquired 10 organizations. Their most recent acquisition was Celltech Therapeutics on May 18, 2004. They acquired Celltech Therapeutics for 0.
|
Date
Company Name
|
Industry | Acquisition Type | Price | |
|---|---|---|---|---|
|
May 18, 2004
|
Biotechnology | acquisition | — | Detail |
|
Jan 1, 2006
Intranasal Therapeutics
|
Biotechnology | acquisition | — | Detail |
|
Sep 25, 2006
Schwarz Pharma AG
|
Medical | acquisition | € 4.40M | Detail |
|
Nov 22, 2011
Lectus Therapeutics
|
Biotechnology | acquisition | — | Detail |
|
Jun 6, 2017
Beryllium Discovery
|
Biotechnology | acquisition | — | Detail |
